Aberrant EGFR signaling leads to poor prognosis and low survival rates for GBM patients, poor responses to therapy, and earlier recurrence after treatment [13,17] and therefore EGFR-targeted therapy has emerged as a promising approach for the management of gliomas [12,13,14,15,16,17,18]. The gene discussed is EGFR; the disease is glioblastoma.